28.62
-0.4153(-1.43%)
Currency In USD
| Previous Close | 29.04 |
| Open | 29.3 |
| Day High | 29.3 |
| Day Low | 28.45 |
| 52-Week High | 62.45 |
| 52-Week Low | 22.24 |
| Volume | 144,368 |
| Average Volume | 1.19M |
| Market Cap | 1.67B |
| PE | -4.08 |
| EPS | -7.01 |
| Moving Average 50 Days | 39.4 |
| Moving Average 200 Days | 34.95 |
| Change | -0.42 |
If you invested $1000 in Agios Pharmaceuticals, Inc. (AGIO) 10 years ago, it would be worth $443.18 as of November 28, 2025 at a share price of $28.625. Whereas If you bought $1000 worth of Agios Pharmaceuticals, Inc. (AGIO) shares 5 years ago, it would be worth $617.98 as of November 28, 2025 at a share price of $28.625.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease
GlobeNewswire Inc.
Nov 19, 2025 12:00 PM GMT
Trial met primary endpoint of hemoglobin response and key secondary endpoints of change from baseline in hemoglobin concentration and indirect bilirubin Trial showed trend favoring mitapivat but did not meet statistical significance in primary endpoi
Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition
GlobeNewswire Inc.
Nov 03, 2025 2:01 PM GMT
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that new data o
Agios’ PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia
GlobeNewswire Inc.
Oct 17, 2025 12:00 PM GMT
CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the Commit